Ceribell to Report First Quarter 2025 Financial Results on May 8, 2025
Ceribell (Nasdaq: CBLL), a medical technology company specializing in neurological condition diagnostics, has scheduled its Q1 2025 financial results announcement for May 8, 2025, after market close. The company will host a conference call at 1:30 p.m. PT / 4:30 p.m. ET on the same day to discuss the results.
Investors can participate by dialing (800) 715-9871 (domestic) or (646) 307-1963 (international) with access code 7370458. A webcast will be available live and archived in the Investor Relations section of Ceribell's website.
Ceribell (Nasdaq: CBLL), un'azienda di tecnologia medica specializzata nella diagnostica delle condizioni neurologiche, ha programmato l'annuncio dei risultati finanziari del primo trimestre 2025 per l'8 maggio 2025, dopo la chiusura del mercato. La società terrà una conference call alle 13:30 PT / 16:30 ET dello stesso giorno per discutere i risultati.
Gli investitori possono partecipare chiamando il numero (800) 715-9871 (nazionale) o (646) 307-1963 (internazionale) con il codice di accesso 7370458. Una webcast sarà disponibile in diretta e archiviata nella sezione Relazioni con gli Investitori del sito web di Ceribell.
Ceribell (Nasdaq: CBLL), una empresa de tecnología médica especializada en el diagnóstico de condiciones neurológicas, ha programado el anuncio de sus resultados financieros del primer trimestre de 2025 para el 8 de mayo de 2025, después del cierre del mercado. La compañía realizará una conferencia telefónica a la 1:30 p.m. PT / 4:30 p.m. ET ese mismo día para analizar los resultados.
Los inversores pueden participar llamando al (800) 715-9871 (nacional) o al (646) 307-1963 (internacional) con el código de acceso 7370458. Habrá una transmisión en vivo disponible y archivada en la sección de Relaciones con Inversores del sitio web de Ceribell.
Ceribell (나스닥: CBLL)는 신경학적 질환 진단을 전문으로 하는 의료 기술 회사로, 2025년 5월 8일 장 마감 후 2025년 1분기 재무 실적 발표를 예정하고 있습니다. 같은 날 오후 1시 30분 PT / 오후 4시 30분 ET에 실적을 논의하는 컨퍼런스 콜을 개최할 예정입니다.
투자자들은 국내 전화 (800) 715-9871 또는 국제 전화 (646) 307-1963에 접속 코드 7370458을 입력하여 참여할 수 있습니다. 웹캐스트는 실시간으로 제공되며 Ceribell 웹사이트의 투자자 관계 섹션에 아카이브로도 게시됩니다.
Ceribell (Nasdaq : CBLL), une entreprise de technologie médicale spécialisée dans le diagnostic des troubles neurologiques, a prévu l'annonce de ses résultats financiers du premier trimestre 2025 le 8 mai 2025, après la clôture du marché. La société organisera une conférence téléphonique à 13h30 PT / 16h30 ET le même jour pour discuter des résultats.
Les investisseurs peuvent participer en appelant le (800) 715-9871 (national) ou le (646) 307-1963 (international) avec le code d'accès 7370458. Un webcast sera disponible en direct et archivé dans la section Relations Investisseurs du site web de Ceribell.
Ceribell (Nasdaq: CBLL), ein Medizintechnikunternehmen, das sich auf die Diagnostik neurologischer Erkrankungen spezialisiert hat, hat die Veröffentlichung der Finanzergebnisse für das erste Quartal 2025 für den 8. Mai 2025 nach Börsenschluss angekündigt. Am selben Tag findet um 13:30 Uhr PT / 16:30 Uhr ET eine Telefonkonferenz zur Besprechung der Ergebnisse statt.
Investoren können teilnehmen, indem sie die Nummer (800) 715-9871 (national) oder (646) 307-1963 (international) mit dem Zugangscode 7370458 wählen. Ein Webcast wird live verfügbar sein und im Bereich Investor Relations auf der Ceribell-Website archiviert.
- None.
- None.
SUNNYVALE, Calif., April 24, 2025 (GLOBE NEWSWIRE) -- CeriBell, Inc. (Nasdaq: CBLL) (“Ceribell”), a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions, today announced that it will release financial results for the first quarter of 2025 after the close of trading on Thursday, May 8, 2025. Company management will host a conference call to discuss financial results beginning at 1:30 p.m. PT / 4:30 p.m. ET on May 8, 2025.
Investors interested in listening to the conference call may do so by dialing (800) 715-9871 for domestic callers or (646) 307-1963 for international callers and providing access code 7370458. A live and archived webcast of the event will be available in the "Investor Relations" section of the Ceribell website at https://investors.ceribell.com/.
About CeriBell, Inc.
Ceribell is a medical technology company focused on transforming the diagnosis and management of patients with serious neurological conditions. Ceribell has developed the Ceribell System, a novel, point-of-care electroencephalography (“EEG”) platform specifically designed to address the unmet needs of patients in the acute care setting. By combining proprietary, highly portable, and rapidly deployable hardware with sophisticated artificial intelligence (“AI”)-powered algorithms, the Ceribell System enables rapid diagnosis and continuous monitoring of patients with neurological conditions. The Ceribell System is FDA 510(k) cleared for indicating suspected seizure activity and currently utilized in intensive care units and emergency rooms across the U.S. Ceribell is headquartered in Sunnyvale, California. For more information, please visit www.ceribell.com or follow the company on LinkedIn.
Investor Contact
Brian Johnston or Laine Morgan
Gilmartin Group
Investors@ceribell.com
Media Contact
Corrie Rose
Press@ceribell.com
FAQ
When will Ceribell (CBLL) release its Q1 2025 earnings?
How can investors join Ceribell's Q1 2025 earnings call?
What time is Ceribell's (CBLL) Q1 2025 earnings conference call?
Where can I find the replay of Ceribell's Q1 2025 earnings webcast?
